NanoViricides shares surge 10.74% after-hours as company highlights NV-387's broad-spectrum antiviral efficacy at Pharma Partnering Summit 2025.

NanoViricides surged 10.74% in after-hours trading following its announcement to present at the Pharma Partnering Summit 2025, highlighting its Phase II antiviral drug NV-387. The company emphasized NV-387’s broad-spectrum efficacy against viruses like H3N2, RSV, and MPox, noting its unique mechanism to prevent viral escape and potential as a first-line treatment for respiratory infections. The presentation underscored progress in advancing NV-387 toward Phase II trials in the DRC for MPox and its applicability to unmet medical needs in influenza, measles, and smallpox. The event also showcased the company’s platform technology, including pipeline candidates for herpesviruses and HIV, and highlighted NV-387’s market potential exceeding $20 billion. The news reinforced investor confidence in NanoViricides’ innovative antiviral pipeline and strategic partnerships.